RxDoctor Payments Data

Leslie Markle, MD

Dermatology · Tyler, TXNPI 1225264443

Payments from drug & device makers

$9,662in general payments, 2019–2025

Across 504 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$953
  • Lilly USA, LLC$539
  • Novartis$396
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$2082%
  • Food & beverage$9,15695%
  • Education$2983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,662 in reported general payments places this provider in the 65th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$596,310
Medicare patients
1,724
Services billed
10,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab58$253,644
Cosentyx Sensoready (2 Pens)Secukinumab27$197,684
Taltz AutoinjectorIxekizumab20$126,981
Enbrel SureclickEtanercept16$115,894
Humira(Cf) PenAdalimumab12$84,487
XolairOmalizumab29$82,450
OlumiantBaricitinib14$38,360
Betamethasone Dipropionate200$7,098
Ketoconazole213$3,697
Doxycycline Hyclate136$2,622
Clobetasol Propionate74$2,461
Triamcinolone Acetonide173$2,272
Hydroxychloroquine Sulfate65$2,155
Metronidazole26$1,536
Fluorouracil20$1,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$539$38,36014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →